Johnson & Johnson (JNJ) Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal second quarter and six months ended June 28, 2026. Johnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. The company is a large accelerated filer. A key strategic development is the ongoing planned separation of the Orthopaedics business, announced in October 2025, with a targeted completion within 18 to 24 months.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Sales to Customers | $25.31 Billion | $23.74 Billion | $49.37 Billion | $45.64 Billion |
| Net Earnings | $5.53 Billion | $5.54 Billion | $10.77 Billion | $16.54 Billion |
| Diluted EPS | $2.27 | $2.29 | $4.41 | $6.82 |
| Gross Margin | 68.2% | 67.9% | 67.3% | 67.2% |
| Operating Cash Flow (6mo) | $11.13 Billion | |||
| Cash & Equivalents | $20.42 Billion (as of June 28, 2026) | |||
| Total Debt | $49.04 Billion ($11.69B Current + $37.34B Long-term) |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 6.6% in Q2 and 8.2% for the six months, driven by operational growth of 5.6% and 6.0% respectively. Currency had a positive impact of 1.0% in Q2 and 2.2% for the six months.
- Earnings Volatility: While Q2 net earnings remained flat year-over-year, six-month earnings dropped significantly ($10.77B vs $16.54B). This decline is primarily due to a $7.0 billion reversal of the talc litigation reserve recorded in Q1 2025, which boosted prior-year results. Excluding this one-time item, underlying profitability remains stable.
- Product Performance:
- Growth Drivers: Oncology sales grew 17.3% (Q2) led by DARZALEX, CARVYKTI, and TECVAYLI. Neuroscience grew 14.0% driven by SPRAVATO and CAPLYTA (acquired in 2025). TREMFYA in Immunology grew 72.5%.
- Declines: STELARA sales declined 55.2% (Q2) due to biosimilar competition. IMBRUVICA declined 18.6% due to competitive pressures.
- Restructuring: The company initiated a new supply chain restructuring program in Innovative Medicine in Q2 2026, recording $200 million in expenses (primarily asset impairments). Total restructuring costs for the six months were $338 million.
Guidance, Outlook, and Risks
- Orthopaedics Separation: The company continues to explore paths to separate its Orthopaedics business. Costs related to this separation were $0.3 billion in Q2 and $0.4 billion for the six months.
- Legal Contingencies:
- Talc Litigation: Approximately 76,000 plaintiffs remain in pending lawsuits. The company maintains a reserve of approximately $3.7 billion for talc-related matters. The company is actively defending against claims and has filed motions to dismiss in the multi-district litigation (MDL).
- Patent Challenges: Significant litigation is ongoing regarding patents for key products including INVEGA SUSTENNA, ERLEADA, SPRAVATO, CAPLYTA, and SIMPONI. Generic and biosimilar entry remains a primary risk to future revenue.
- Acquisitions: In June 2026, JNJ announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash, expected to close in Q3 2026.
- Liquidity: The company maintains a strong liquidity position with $20.8 billion in cash and marketable securities and access to a $12.5 billion credit facility secured in June 2026.
Investor Verification Checklist
- Talc Reserve Adequacy: Verify the sufficiency of the $3.7 billion talc reserve given the ongoing litigation volume (76,000 plaintiffs) and recent court rulings on causation.
- STELARA Trajectory: Monitor the rate of STELARA sales decline as biosimilar competition intensifies in both U.S. and international markets.
- Orthopaedics Separation Timeline: Track progress on the planned separation of the Orthopaedics business to ensure it meets the 18-24 month target and does not incur unexpected costs.
- Patent Expirations: Review the status of patent litigation for high-revenue products (e.g., DARZALEX, ERLEADA, SIMPONI) to assess risks of generic/biosimilar erosion.
- Restructuring Execution: Monitor the execution of the new Innovative Medicine supply chain restructuring to ensure projected cost savings are realized.